Cardiff Oncology Inc. Skyrockets, Piper Sandler Sets $7 Price Target. In a significant development that has caught the attention of investors, Cardiff Oncology Inc. (NASDAQ: CRDF) saw an impressive 24% surge in their stock price yesterday, closing at $3.58. This sudden upswing comes amidst positive sentiments from leading investment banking and institutional securities firm, Piper Sandler, which has set a bullish price target of ...
The stock market started off on a good note and really picked up speed at 10 pm (GST +8) after a very positive ISM Manufacturing report, which showed just the right balance of growth without too much inflation. On top of that, the tech sector, which was already doing well, received an extra boost from a highly praised report by DELL. By the end of the trading session, stocks closed near their highest points for the day, with more stocks reaching new highs on both maj...
Cardiff Oncology Beats Q4 Earnings and Revenue Estimates: What it Means for Investors. Cardiff Oncology (NASDAQ: $CRDF), a clinical-stage biotechnology company, has just reported its fourth quarter results. The company beat analyst consensus estimates on both earnings and revenue, marking a significant milestone in its financial performance.$Cardiff Oncology(CRDF.US)$ https://stockregion.app/p/clinical-stage-oncology-company-beats
$Cardiff Oncology(CRDF.US)$Director PACE GARY W purchased 30,000 shares of Common Stocks on Dec 19, 2023 at an average price of $1.37 for a total value of $41,100.
$Cardiff Oncology(CRDF.US)$I dont put a lot of stock in most analysts predictions and PT. It seems in most cases if you have a 9th grade education, you can be one? But lots of people treat them as gospol with updated PT and ratings! But this time i agree! And you can read some of why i do from earlier posts. Cardiff Oncology has an analyst consensus of Strong Buy, with a price target consensus of $7.33.
Cardiff Oncology股票讨论区
Oncology Stock Spikes 24% Amidst Investment Firm's New Price Target
In a significant development that has caught the attention of investors, Cardiff Oncology Inc. (NASDAQ: CRDF) saw an impressive 24% surge in their stock price yesterday, closing at $3.58. This sudden upswing comes amidst positive sentiments from leading investment banking and institutional securities firm, Piper Sandler, which has set a bullish price target of ...
🤘🏻
Market Summary 1st March 2024
Clinical-stage Oncology Company Beats Q4 Earnings & Revenue Estimates
Cardiff Oncology (NASDAQ: $CRDF), a clinical-stage biotechnology company, has just reported its fourth quarter results. The company beat analyst consensus estimates on both earnings and revenue, marking a significant milestone in its financial performance. $Cardiff Oncology(CRDF.US)$
https://stockregion.app/p/clinical-stage-oncology-company-beats
Insider buy
A bit more.
暂无评论